BACKGROUND: Mutations in the TMPRSS3 gene, although rare, can cause high frequency hearing loss with residual hearing at low frequencies. Several previous studies have reported cochlear implant (CI) outcomes for adults with TMPRSS3 mutation with mixed results. Although some studies have suggested that TMPRSS3 is expressed in spiral ganglion cells, it remains unclear if previously reported poor CI outcomes in this population were secondary to long durations of deafness or to the effects of the TMPRSS3 mutation. To date, no studies in the literature have reported CI outcomes for children with TMPRSS3 mutation treated with CI. OBJECTIVE: The current case series aimed to describe outcomes for three children with sloping hearing loss caused by TMPRSS3 mutation who underwent bilateral CI. STUDY DESIGN: Case series. SETTING: Academic medical center. PATIENTS: Three children (3-4 yr) with TMPRSS3 mutation and normal sloping to profound high frequency hearing loss. INTERVENTIONS: CI and electric acoustic stimulation (EAS). MAIN OUTCOME MEASURES: Outcome measures were residual hearing thresholds, speech recognition scores, and electrode placement determined via intraoperative CT imaging. RESULTS: All three children maintained residual acoustic hearing and received benefit from EAS. Mean change in low-frequency pure-tone average was 17 dB. Mean postoperative word and sentence recognition scores in the bilateral EAS condition were 80 and 75%, respectively. CONCLUSIONS: Results indicate that CI with EAS is an appropriate treatment for children with TMPRSS3 genetic mutation. Pediatric results from this case series show more favorable CI outcomes than are currently reported for adults with TMPRSS3 mutation suggesting that the intervention may be time sensitive.
BACKGROUND: Mutations in the TMPRSS3 gene, although rare, can cause high frequency hearing loss with residual hearing at low frequencies. Several previous studies have reported cochlear implant (CI) outcomes for adults with TMPRSS3 mutation with mixed results. Although some studies have suggested that TMPRSS3 is expressed in spiral ganglion cells, it remains unclear if previously reported poor CI outcomes in this population were secondary to long durations of deafness or to the effects of the TMPRSS3 mutation. To date, no studies in the literature have reported CI outcomes for children with TMPRSS3 mutation treated with CI. OBJECTIVE: The current case series aimed to describe outcomes for three children with sloping hearing loss caused by TMPRSS3 mutation who underwent bilateral CI. STUDY DESIGN: Case series. SETTING: Academic medical center. PATIENTS: Three children (3-4 yr) with TMPRSS3 mutation and normal sloping to profound high frequency hearing loss. INTERVENTIONS: CI and electric acoustic stimulation (EAS). MAIN OUTCOME MEASURES: Outcome measures were residual hearing thresholds, speech recognition scores, and electrode placement determined via intraoperative CT imaging. RESULTS: All three children maintained residual acoustic hearing and received benefit from EAS. Mean change in low-frequency pure-tone average was 17 dB. Mean postoperative word and sentence recognition scores in the bilateral EAS condition were 80 and 75%, respectively. CONCLUSIONS: Results indicate that CI with EAS is an appropriate treatment for children with TMPRSS3 genetic mutation. Pediatric results from this case series show more favorable CI outcomes than are currently reported for adults with TMPRSS3 mutation suggesting that the intervention may be time sensitive.
Authors: Henryk Skarzynski; Artur Lorens; Beata Dziendziel; Piotr H Skarzynski Journal: Int J Pediatr Otorhinolaryngol Date: 2015-09-06 Impact factor: 1.675
Authors: Robert W Eppsteiner; A Eliot Shearer; Michael S Hildebrand; Adam P Deluca; Haihong Ji; Camille C Dunn; Elizabeth A Black-Ziegelbein; Thomas L Casavant; Terry A Braun; Todd E Scheetz; Steven E Scherer; Marlan R Hansen; Bruce J Gantz; Richard J H Smith Journal: Hear Res Date: 2012-08-28 Impact factor: 3.208
Authors: Lydie Fasquelle; Hamish S Scott; Marc Lenoir; Jing Wang; Guy Rebillard; Sophie Gaboyard; Stéphanie Venteo; Florence François; Anne-Laure Mausset-Bonnefont; Stylianos E Antonarakis; Elizabeth Neidhart; Christian Chabbert; Jean-Luc Puel; Michel Guipponi; Benjamin Delprat Journal: J Biol Chem Date: 2011-03-21 Impact factor: 5.157
Authors: Matthew L Carlson; Brendan P O'Connell; Christine M Lohse; Colin L Driscoll; Alex D Sweeney Journal: Otol Neurotol Date: 2018-01 Impact factor: 2.311
Authors: Michel Guipponi; Min-Yen Toh; Justin Tan; Daeho Park; Kelly Hanson; Ester Ballana; David Kwong; Ping Z F Cannon; Qingyu Wu; Alex Gout; Mauro Delorenzi; Terence P Speed; Richard J H Smith; Henrik H Dahl; Michael Petersen; Rohan D Teasdale; Xavier Estivill; Woo Jin Park; Hamish S Scott Journal: Hum Mutat Date: 2008-01 Impact factor: 4.878
Authors: Miriam Elbracht; Jan Senderek; Thomas Eggermann; Christian Thürmer; Jonas Park; Martin Westhofen; Klaus Zerres Journal: J Med Genet Date: 2007-06 Impact factor: 6.318
Authors: Dong Woo Nam; Sang Soo Park; So Min Lee; Myung-Whan Suh; Moo Kyun Park; Jae-Jin Song; Byung Yoon Choi; Jun Ho Lee; Seung Ha Oh; Kyung Chul Moon; Yo Han Ahn; Hee Gyung Kang; Hae Il Cheong; Ji Hyun Kim; Sang-Yeon Lee Journal: Biomed Res Int Date: 2022-09-09 Impact factor: 3.246